MedTrace Logo

Tumor Necrosis Factor-alpha Levels and Cardiac Functions in Type 1 Diabetes Mellitus

NCT06129448 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-04-25

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effect of type 1 diabetes mellitus on cardiac functions and evaluate the correlation of the dysfunction with the tumor necrosis factor-α (TNF-α) an inflammation-related factor. The study population will be the patients with the diagnosis of type 1 diabetes mellitus and the healthy children es the control group. The main question\[s\] it aims to answer are:

* Is diabetes affecting the systolic and diastolic cardiac functions
* Is diabetes affecting the left and the right ventricles equally?
* Does diabetes status, as assessed by HbA1c, have an impact on the occurrence of cardiac dysfunction?
* Is TNF-α can be a marker for early diagnosis of cardiac dysfunction? Diabetic patients will be examined by both a pediatric endocrinologist and a pediatric cardiologist. Transthoracic echocardiography will be performed and TNF-α will be evaluated for both the diabetic patients and the healthy children.

Conditions

  • Diabetes Mellitus, Type 1
  • Systolic Dysfunction
  • Diastolic Dysfunction

Interventions

DIAGNOSTIC_TEST

transthoracic echocardiography

All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.

Sponsors & Collaborators

  • Sirnak State Hospital

    lead OTHER_GOV

Principal Investigators

  • MERVE MA AYDEMİR · Sirnak State Hospital

  • Tahir Çağdaş · Sirnak State Hospital

  • Özge Doğan · Sirnak State Hospital

  • Veysel Tahiroğlu · Şırnak Üniversitesi

  • Cem Mete · Sirnak State Hospital

  • Hasan Karageçili · Siirt University

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-01-30
Completion
2024-02-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06129448 on ClinicalTrials.gov